Compare LODE & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LODE | CHRS |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.8M | 177.7M |
| IPO Year | 2004 | 2014 |
| Metric | LODE | CHRS |
|---|---|---|
| Price | $2.56 | $1.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $4.00 | ★ $5.51 |
| AVG Volume (30 Days) | ★ 1.1M | 1.1M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 63.55 | ★ 472.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,553,796.00 | N/A |
| Revenue This Year | $1,582.85 | $73.08 |
| Revenue Next Year | $246.20 | $30.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.35 | $1.09 |
| 52 Week High | $4.98 | $2.62 |
| Indicator | LODE | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 32.76 | 37.82 |
| Support Level | $2.39 | N/A |
| Resistance Level | $3.61 | $1.53 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 17.93 | 0.00 |
Comstock Inc commercializes technologies that convert underutilized waste and natural resources into clean energy and supporting products, including electrification, metals, and minerals from end-of-life solar panels. Its subsidiary focuses on producing renewable fuels from waste, energy crops, and woody biomass, supported by facilities in Wisconsin, pilot farms, a biorefinery site in Tulsa, and solar panel recycling operations in Nevada. The Company operates through two high-growth segments and a corporate segment, with its activities grouped into Metals, which generates the majority of revenue, Fuels, Mining, Strategic Investments, and Corporate Services.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.